 |
141 Diseases |  |
27 Trials |
|
27 Trials |  |
1501 News |  |
| «1234567891011» |
- | Somavert (pegvisomant) / Pfizer
Trial completion date, Trial primary completion date: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=51, Recruiting, Sponsor: Cedars-Sinai Medical Center
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- || paltusotine (CRN00808) / Crinetics
New P2 trial: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (clinicaltrials.gov) - Jan 3, 2019
P2, N=40, Recruiting, Sponsor: Crinetics Pharmaceuticals Inc.
- | octreotide acetate / Generic mfg.
Trial completion, Phase classification: Ultrasound Guided Octreotide LAR Injection in Acromegaly (clinicaltrials.gov) - Sep 11, 2018
P4, N=15, Completed, Sponsor: Cedars-Sinai Medical Center
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Mar 2020 Recruiting --> Completed | Phase classification: PN/A --> P4
- ||||| Inlyta (axitinib) / Pfizer
Enrollment open, Enrollment change, Combination therapy, Metastases: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (clinicaltrials.gov) - Aug 6, 2018
P2/3, N=148, Recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Recruiting --> Completed | Phase classification: PN/A --> P4 Active, not recruiting --> Recruiting | N=105 --> 148
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Aug 6, 2018
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Recruiting | N=105 --> 148 Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion, Enrollment change, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jul 30, 2018
P=N/A, N=22, Completed, Sponsor: Ipsen
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 Recruiting --> Completed | N=100 --> 22
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly. (Pubmed Central) - Jun 27, 2018
Pituitary surgery alone was more effective than primary medical treatment (p = 0.006), and the combination of surgery followed by medical therapy was even more effective (p < 0.0001). Subjects treated with medical therapy after surgical debulking had a significant improvement in response rate compared to matched subjects treated with primary medical therapy.
- ||||| Inlyta (axitinib) / Pfizer
Enrollment closed, Enrollment change, Combination therapy, Metastases: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (clinicaltrials.gov) - Jun 11, 2018
P2/3, N=105, Active, not recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Subjects treated with medical therapy after surgical debulking had a significant improvement in response rate compared to matched subjects treated with primary medical therapy. Recruiting --> Active, not recruiting | N=253 --> 105
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2 trial, Combination therapy: Tolvaptan-Octreotide LAR Combination in ADPKD (clinicaltrials.gov) - May 31, 2018
P2, N=20, Not yet recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date: Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber (clinicaltrials.gov) - Apr 20, 2018
P2, N=15, Active, not recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting | N=253 --> 105 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Oct 2018 | Trial primary completion date: Oct 2017 --> Jul 2018
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion date, Trial primary completion date: OCEAN: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias (clinicaltrials.gov) - Apr 19, 2018
P2/3, N=62, Recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Oct 2018 | Trial primary completion date: Oct 2017 --> Jul 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- ||||||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion: PAOLA: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (clinicaltrials.gov) - Apr 6, 2018
P3, N=198, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Active, not recruiting --> Completed
- ||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Mar 5, 2018
P4, N=52, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: May 2023 --> May 2023 | Initiation date: May 2013 --> May 2013 | Trial primary completion date: May 2023 --> May 2023
- | everolimus / Generic mfg., Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, P3 data, Journal: Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. (Pubmed Central) - Jan 31, 2018
P3
No significant difference in OS was observed for the everolimus plus octreotide LAR and placebo plus octreotide LAR arms of the RADIANT-2 study, even after adjusting for imbalances in the baseline covariates. NCT00412061, www.clinicaltrials.gov.
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial primary completion date, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jan 30, 2018
P=N/A, N=100, Recruiting, Sponsor: Ipsen
NCT00412061, www.clinicaltrials.gov. Trial primary completion date: Feb 2018 --> Jun 2018
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion: ALADIN2: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (clinicaltrials.gov) - Jan 10, 2018
P3, N=100, Completed, Sponsor: Mario Negri Institute for Pharmacological Research
Trial primary completion date: Feb 2018 --> Jun 2018 Active, not recruiting --> Completed
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Metastases: EVERLAR: Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (clinicaltrials.gov) - Jan 3, 2018
P2, N=43, Completed, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Trial completion: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Dec 27, 2017
P2a, N=28, Completed, Sponsor: Ipsen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | octreotide acetate / Generic mfg.
Enrollment change, Trial termination, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Dec 7, 2017
P2, N=62, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=140 --> 62 | Recruiting --> Terminated
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Phase classification, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Oct 20, 2017
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=140 --> 62 | Recruiting --> Terminated Phase classification: P2 --> P4
- |||| octreotide acetate / Generic mfg.
Enrollment open, Enrollment change, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Sep 28, 2017
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P2 --> P4 Active, not recruiting --> Recruiting | N=62 --> 140
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
New P4 trial, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Sep 26, 2017
P4, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
New P2 trial, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Sep 20, 2017
P2, N=50, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Lutathera (lutetium Lu 177 dotatate) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
Review, Journal: Radionuclide Therapy for Neuroendocrine Tumors. (Pubmed Central) - Sep 1, 2017
Recently, the phase III, randomized NETTER-1 trial has compared (177)Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment closed, Trial primary completion date: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (clinicaltrials.gov) - Aug 29, 2017
P2a, N=28, Active, not recruiting, Sponsor: Ipsen
This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Nov 2017
- | Journal: Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. (Pubmed Central) - Aug 27, 2017
P3
Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week...Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria (9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%). Conclusion No significant differences in PFS were observed between the bevacizumab and IFN arms, which suggests that these agents have similar antitumor activity among patients with advanced NETs.
- |||||| Inlyta (axitinib) / Pfizer, octreotide acetate / Generic mfg.
Enrollment open, Phase classification, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (clinicaltrials.gov) - Aug 24, 2017
P2/3, N=253, Recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Conclusion No significant differences in PFS were observed between the bevacizumab and IFN arms, which suggests that these agents have similar antitumor activity among patients with advanced NETs. Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=80 --> 253 | Trial primary completion date: Jul 2015 --> Nov 2019
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. (Pubmed Central) - Jul 8, 2017
P3
Active, not recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=80 --> 253 | Trial primary completion date: Jul 2015 --> Nov 2019 Lanreotide depot/autogel is effective for the control of CS symptoms in patients (SSA-naïve or experienced) with NETs.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: ALADIN2: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (clinicaltrials.gov) - Jul 7, 2017
P3, N=98, Active, not recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Lanreotide depot/autogel is effective for the control of CS symptoms in patients (SSA-naïve or experienced) with NETs. Trial primary completion date: Jun 2017 --> Dec 2017
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Definition and classification of chyle leak after pancreatic operation: A consensus statement by the International Study Group on Pancreatic Surgery. (Pubmed Central) - Jul 7, 2017
This classification and grading system for chyle leak after pancreatic resection allows for comparison of outcomes between series. As with the other the International Study Group on Pancreatic Surgery consensus statements, this classification should facilitate communication and evaluation of different approaches to the prevention and treatment of this complication.
- |||| Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly (clinicaltrials.gov) - Jul 4, 2017
P3, N=358, Completed, Sponsor: Novartis Pharmaceuticals
As with the other the International Study Group on Pancreatic Surgery consensus statements, this classification should facilitate communication and evaluation of different approaches to the prevention and treatment of this complication. Trial primary completion date: Dec 2010 --> Mar 2016
- | everolimus / Generic mfg.
Journal: Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. (Pubmed Central) - Jun 28, 2017
Trial primary completion date: Dec 2010 --> Mar 2016 In addition to prolonging progression-free survival in patients with pNET, everolimus down-regulates excess production of 2 gastrointestinal hormones, which may help control their associated clinical syndromes.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. (Pubmed Central) - Jun 11, 2017
This population-based analysis reveals that carcinoid syndrome is significantly associated with tumour grade, stage, and primary tumour site, and leads to shorter survival compared with those patients without carcinoid syndrome. An improved understanding of the heterogeneity of presenting symptoms among patients with NETs might permit more tailored assessment and management than at present and enable future research into the effect of carcinoid syndrome control on patient survival.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: The impact of SSTR-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. (Pubmed Central) - Jun 8, 2017
The management is changed in more than one third of patients undergoing SSTR PET/CT even when performed after an (111)In-Octreotide scan. Inter-modality changes were three times more likely than intra-modality changes underlining the clinical impact of SSTR PET/CT.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date, Metastases: EVERLAR: Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (clinicaltrials.gov) - May 31, 2017
P2, N=43, Active, not recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Inter-modality changes were three times more likely than intra-modality changes underlining the clinical impact of SSTR PET/CT. Trial primary completion date: Apr 2014 --> Sep 2014
- | everolimus / Generic mfg., Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. (Pubmed Central) - May 18, 2017
Risk for pulmonary or metabolic events was associated with increased everolimus Cmin . Co-administration of everolimus plus octreotide LAR increased octreotide Cmin , which did not impact efficacy.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: ALADIN2: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (clinicaltrials.gov) - May 9, 2017
P3, N=98, Active, not recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Co-administration of everolimus plus octreotide LAR increased octreotide Cmin , which did not impact efficacy. Trial primary completion date: Mar 2017 --> Jun 2017
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment open: Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber (clinicaltrials.gov) - Mar 31, 2017
P2, N=15, Recruiting, Sponsor: Radboud University
Trial primary completion date: Mar 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Enrollment open, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Feb 19, 2017
P=N/A, N=100, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Sandostatin LAR Depot (octreotide acetate) / Novartis, Perjeta (pertuzumab) / Roche
Journal: A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. (Pubmed Central) - Feb 7, 2017
Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.
- Somavert (pegvisomant) / Pfizer
Trial primary completion date: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=51, Recruiting, Sponsor: Cedars-Sinai Medical Center
Results in the well-differentiated carcinoid tumors are thought provoking. Trial primary completion date: Dec 2017 --> Dec 2018
- octreotide acetate / Generic mfg.
Trial completion, Trial primary completion date: Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target (clinicaltrials.gov) - Jan 26, 2017
P4, N=84, Completed, Sponsor: University of Aarhus
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2017
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. (Pubmed Central) - Jan 20, 2017
P3
Methods We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) ((177)Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group)...Clinically significant myelosuppression occurred in less than 10% of patients in the (177)Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .).
- || octreotide acetate / Generic mfg.
Trial primary completion date, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Jan 13, 2017
P2, N=62, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
(Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .). Trial primary completion date: Dec 2017 --> Feb 2017
- || octreotide acetate / Generic mfg.
Trial primary completion date, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Jan 11, 2017
P2, N=62, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Feb 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
New trial, Metastases: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: Ipsen
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Nov 29, 2016
P4, N=52, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Sep 2022 --> May 2023
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Biomarker, New trial, Circulating tumor cells, Tumor cell: Circulating Tumor Cells and Tumor DNA in HCC and NET (clinicaltrials.gov) - Nov 25, 2016
P=N/A, N=130, Recruiting, Sponsor: University of Aarhus
- ||| octreotide acetate / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov) - Nov 2, 2016
P2, N=62, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2022 --> May 2023 N=140 --> 62 | Recruiting --> Active, not recruiting
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial primary completion date: OCEAN: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias (clinicaltrials.gov) - Oct 18, 2016
P2/3, N=62, Recruiting, Sponsor: Radboud University
N=140 --> 62 | Recruiting --> Active, not recruiting Trial primary completion date: Nov 2017 --> Nov 2018